H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a Buy rating on the shares. The firm updated the company’s model after priority review was granted to atacicept.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating
- Undervalued IgAN Opportunity: Buy Rating on VERA Driven by Atacicept’s Robust ORIGIN 3 Data and Long-Term Kidney Disease Upside
- Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity
- Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
- Vera Therapeutics sees cash runway through atacicept commercial launch